216 related articles for article (PubMed ID: 24047196)
1. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.
Baumgarten M; Polanski L; Campbell B; Raine-Fenning N
Hum Fertil (Camb); 2013 Sep; 16(3):168-74. PubMed ID: 24047196
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
Kasum M; Vrčić H; Stanić P; Ježek D; Orešković S; Beketić-Orešković L; Pekez M
Gynecol Endocrinol; 2014; 30(12):845-9. PubMed ID: 25093428
[TBL] [Abstract][Full Text] [Related]
3. Etiology of OHSS and use of dopamine agonists.
Soares SR
Fertil Steril; 2012 Mar; 97(3):517-22. PubMed ID: 22265002
[TBL] [Abstract][Full Text] [Related]
4. Physiology and pathology of ovarian hyperstimulation syndrome.
Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
[TBL] [Abstract][Full Text] [Related]
5. GnRH-agonist triggering to avoid ovarian hyperstimulation syndrome: a review of the evidence.
Martinez MC; Ruiz FJ; García-Velasco JA
Curr Drug Targets; 2013 Jul; 14(8):843-9. PubMed ID: 23614678
[TBL] [Abstract][Full Text] [Related]
6. [Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
Kozovski G; Angelova M; Kacarova P
Akush Ginekol (Sofiia); 2014; 53(5):34-5. PubMed ID: 25558669
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
[TBL] [Abstract][Full Text] [Related]
8. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists.
Garcia-Velasco JA
Reprod Biomed Online; 2009; 18 Suppl 2():71-5. PubMed ID: 19406035
[TBL] [Abstract][Full Text] [Related]
9. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
Kalampokas T; Creatsas G; Kalampokas E
Gynecol Endocrinol; 2013 Feb; 29(2):98-100. PubMed ID: 23110560
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of ovarian hyperstimulation syndrome.
Nelson SM
Thromb Res; 2017 Mar; 151 Suppl 1():S61-S64. PubMed ID: 28262238
[TBL] [Abstract][Full Text] [Related]
12. Etiology of ovarian hyperstimulation syndrome.
Orvieto R
Fertil Steril; 2012 Jun; 97(6):e27; author reply e28. PubMed ID: 22503413
[No Abstract] [Full Text] [Related]
13. Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome.
Kasum M; Orešković S; Franulić D; Čehić E; Lila A; Vujić G; Grgić F
Acta Clin Croat; 2017 Mar; 56(1):133-142. PubMed ID: 29120551
[TBL] [Abstract][Full Text] [Related]
14. Preventing ovarian hyperstimulation syndrome: guidance for the clinician.
Humaidan P; Quartarolo J; Papanikolaou EG
Fertil Steril; 2010 Jul; 94(2):389-400. PubMed ID: 20416867
[TBL] [Abstract][Full Text] [Related]
15. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
[TBL] [Abstract][Full Text] [Related]
16. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
17. High dose cabergoline in management of ovarian hyperstimulation syndrome.
Ata B; Seyhan A; Orhaner S; Urman B
Fertil Steril; 2009 Sep; 92(3):1168.e1-1168.e4. PubMed ID: 19539908
[TBL] [Abstract][Full Text] [Related]
18. Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists.
Busso CE; Garcia-Velasco J; Gomez R; Alvarez C; Simón C; Pellicer A
Reprod Biomed Online; 2009 Jul; 19(1):43-51. PubMed ID: 19573289
[TBL] [Abstract][Full Text] [Related]
19. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
20. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
